HC Wainwright restated their buy rating on shares of Rockwell Medical (NASDAQ:RMTI – Free Report) in a report published on Wednesday morning, Benzinga reports. HC Wainwright currently has a $9.00 price objective on the stock.
Separately, StockNews.com raised Rockwell Medical from a sell rating to a hold rating in a report on Wednesday, June 19th.
View Our Latest Report on RMTI
Rockwell Medical Price Performance
Rockwell Medical (NASDAQ:RMTI – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.05. Rockwell Medical had a negative return on equity of 6.96% and a negative net margin of 5.06%. The business had revenue of $25.83 million during the quarter, compared to the consensus estimate of $23.01 million. During the same quarter last year, the company earned ($0.18) earnings per share. As a group, equities analysts expect that Rockwell Medical will post -0.03 EPS for the current fiscal year.
Institutional Investors Weigh In On Rockwell Medical
Institutional investors and hedge funds have recently modified their holdings of the company. Armistice Capital LLC raised its position in Rockwell Medical by 22.5% during the second quarter. Armistice Capital LLC now owns 3,221,640 shares of the company’s stock valued at $5,670,000 after acquiring an additional 592,000 shares in the last quarter. Vanguard Group Inc. raised its position in Rockwell Medical by 4.0% during the first quarter. Vanguard Group Inc. now owns 1,118,277 shares of the company’s stock valued at $1,856,000 after acquiring an additional 43,302 shares in the last quarter. Renaissance Technologies LLC raised its position in Rockwell Medical by 877.1% during the second quarter. Renaissance Technologies LLC now owns 102,700 shares of the company’s stock valued at $181,000 after acquiring an additional 92,189 shares in the last quarter. Finally, SkyOak Wealth LLC raised its position in Rockwell Medical by 47.3% during the first quarter. SkyOak Wealth LLC now owns 25,110 shares of the company’s stock valued at $42,000 after acquiring an additional 8,065 shares in the last quarter. Institutional investors and hedge funds own 23.31% of the company’s stock.
Rockwell Medical Company Profile
Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.
Read More
- Five stocks we like better than Rockwell Medical
- What is the NASDAQ Stock Exchange?
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- Financial Services Stocks Investing
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- What Investors Need to Know to Beat the Market
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.